NCT03015129View on ClinicalTrials.gov

A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

December 30, 2022

Study Completion Date

December 30, 2022

Conditions
Endometrial CancerEndometrial CarcinosarcomaEndometrial CarcinomaEndometrial Cancer RecurrentEndometrial Carcinoma, Recurrent
Interventions
DRUG

Durvalumab

DRUG

Tremelimumab

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

Unknown

Memorial Sloan Kettering Westchester, Harrison

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03015129 - A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer | Biotech Hunter | Biotech Hunter